- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV-MyoAAV 4E Rep-Cap plasmid (serotype MyoAAV 4E - specific AAV RC-MyoAAV 4E plasmids) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi's MyoAAV 4E Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the MyoAAV 4E capsid protein.
You can produce MyoAAV 4E particle in 293T cell line in high titer using GeneMedi's MyoAAV 4E Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
MyoAAV4E can be considered as a new evolutionary form of MyoAAV4A with possible overloading of the properties, for example, enshrine improved characteristics, including transduction efficiency, uptake to specific muscle tissue or reduced sensitivity to the immune system. This variant might employ both capsid alterations and distinct promoter/enhancer motifs to deliver genes and accomplish transcription solely in muscle cells.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.
Go to AAV
vector system
>>
Manual
Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-RC34 | AAV-MyoAAV 4E Rep-Cap Plasmid (Amp resistance) Size：5ug | Academic | 2062 | ||
| P-RC34 | AAV-MyoAAV 4E Rep-Cap Plasmid (Amp resistance) Size：5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC34 | AAV-MyoAAV 4E Rep-Cap Plasmid (Amp resistance) Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC34 | AAV-MyoAAV 4E Rep-Cap Plasmid (Amp resistance) Size：≥10mg |
All | |||
| P-RC34-Kan | AAV-MyoAAV 4E Rep-Cap Plasmid (Kan resistance) Size：≥10mg |
All | |||
| P-PK34 | AAV-MyoAAV 4E Vector
System (Amp resistance)
1. MyoAAV 4E Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3379 | ||
| P-PK34 | AAV-MyoAAV 4E Vector
System (Amp resistance)
1. MyoAAV 4E Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK34 | AAV-MyoAAV 4E Vector
System (Amp resistance)
1. MyoAAV 4E Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK34 | AAV-MyoAAV 4E Vector
System (Amp resistance)
1. MyoAAV 4E Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK34-Kan | AAV-MyoAAV 4E Vector
System(Kan resistance)
1. MyoAAV 4E Rep-Cap Plasmid(Kan resistance), ≥10mg 2. AAV Helper Plasmid(Kan resistance), ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| [PDF] Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis | Cell Metabolism | 2023/10/3 |
| LITTIP/Lgr6/HnRNPK complex regulates cementogenesis via Wnt signaling | International Journal of Oral Science | 2023/8/9 |
| Targeted Delivery of RGD-CD146+CD271+ Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Promotes Blood-Spinal Cord Barrier Repair after Spinal Cord Injury | ACS Nano | 2023/9/11 |
| Adipocyte-Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer | Advanced Science | 2022/8/17 |
| Akt-mediated mitochondrial metabolism regulates proplatelet formation and platelet shedding post vasopressin exposure | Journal of Thrombosis and Haemostasis | 2022/12/22 |
| CLN7 is an organellar chloride channel regulating lysosomal function | Science advances | 2021/12/15 |
| Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment | ACS Central Science | 2022/5/17 |
| Poly(I:C) preconditioning protects the heart against myocardial ischemia/reperfusion injury through TLR3/PI3K/Akt-dependent pathway | Signal Transduct Target Ther | 2020/11/6 |
| WTAP-mediated m6A modification of FRZB triggers the inflammatory response via the Wnt signaling pathway in osteoarthritis | Experimental & Molecular Medicine | 2024/1/4 |
| MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis | Experimental & Molecular Medicine | 2022/8/30 |
Validation data
No data found
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
